Virtual Library
Start Your Search
A. Ulas
Author of
-
+
P2.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 207)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.01-039 - Clinicopathological Factors in Non-Small Cell Lung Cancer Patients with Bone Metastases (ID 2391)
09:30 - 09:30 | Author(s): A. Ulas
- Abstract
Background:
The bone is one of the most frequent sites for metastases from non-small cell lung cancer (NSCLC) and bone metastases are diagnosed in 30-40% of patients. They are resulted in skeletal-related events (SREs) that associate with an important morbidity and poor survival. In the current study, clinicopathological factors and SRE-free survival were evaluated for patients with NSCLC with bone metastases.
Methods:
Three-hundred and thirty-five NCSLC patients with bone metastases were retrospectively analyzed, between 2010 and 2013. The effect of clinicopathological factors on SRE and survival were evaluated for all patients with or without SREs.
Results:
Totally, 244 (72.8%) patients developed SREs at the diagnosis or during treatment of disease. Of these, 145 required radiotherapy to the bone or pathological fracture, 59 developed malignant hypercalcemia, 21 developed compression fracture of the vertebrae and 5 required surgical treatment of the bone. There were significant differences between the patients with respect to number of bone metastasis, the presence of palliative radiotherapy and the presence of bisphosphonate therapy. The association of histopathological subtypes and bone metastases was not detected. Patients with multiple bone metastasis had significantly increased SRE when compared to patients with single bone metastasis (p=0.002). Patients with single bone metastasis had a better median SRE-free survival compared with patients multiple bone metastasis (7 vs. 2 months, respectively, p<0.0001). Univariate analysis revealed that performance status (PS), the presence of bone metastasis at diagnosis, number of bone metastasis, SRE, the presence of palliative radiotherapy and bisphosphonate therapy were significant prognostic factors for overall survival (OS). Patients with bone metastasis at diagnosis had a shorter median OS compared with patients developed bone metastasis after diagnosis (8 vs. 18 months, respectively, p<0.0001). The presence of bone metastasis at diagnosis and number of bone metastasis were found to be an independent factors for predicting the occurrence of SRE (p<0.001 and p<0.001, respectively).
Conclusion:
Our results showed that the presence of multiple bone metastases was significantly associated with the development of SRE for NSCLC patients with bone metastases. In addition, bone metastasis at diagnosis is related with poor OS. The determining of additional factors affecting the occurrence of SREs may guide to best treatment for NSCLC patients with bone metastases.
